Use access key #2 to skip to page content.

May 2011

Recs

3

Nuclear Power Not the Answer to Climate Change

May 24, 2011 – Comments (9) | RELATED TICKERS: URA , CCJ , UEC

Here is an interesting article written by New Scientist. Absolutely fantastic site/magazine. Feel free to check it out. Its free!   [more]

Recs

6

CorMedix's Eye-Popping Executive Compensation

May 19, 2011 – Comments (0)

    While digging through the most recent 10-K reports for the companies I own/watch I noticed something disturbing with CorMedix (CRMD). I discussed this little known company and its potential in a previous post. Unfortunately I uncovered some stats and numbers that I do not feel comfortable with. Therefore, I feel the need to disclose it with fellow Fools.   [more]

Recs

3

NovaBay Opportunity Emerging

May 19, 2011 – Comments (4) | RELATED TICKERS: NBY

    My favorite small cap pharma pick is getting slammed after announcing Phase II results for its drug NVC-422 for treating eye infections. The study failed to meet its primary endpoint for adenoviral conjunctivitis and has dropped 20% in the past two days. Adenoviral conjuctivitis currently does not have an FDA approved treatment. The company saw encouraging results in the same study against epidemic keratoconjunctivitis (EKC), which is one of the most serious eye infections. A treatment for this disease is highly desired within the ophthalmic community. Despite the unwelcomed results NVC-422 was well tolerated across throughout the study.  [more]

Featured Broker Partners


Advertisement